Anti-FRα antibody-drug conjugate luveltamab tazevibulin for the treatment of FRα-expressing non-small cell lung cancer (AACR 2025) - Mar 26, 2025 - Abstract #3299; Pres time: Apr 28, 2025; 02:00 PM - 05:00 PM; Location: Section 31; Poster Board No: 2; P2 | "Preliminary results from Phase 1 and 2/3 studies in endometrial and ovarian cancer, respectively, show robust clinical activity and enhanced tolerability of luvelta as a single agent and in combination with bevacizumab. Luvelta treatment in tumor-bearing mice also altered tumor immune cell infiltration and activation, demonstrating its ability to modulate the tumor immune microenvironment.In conclusion, the work presented here provides support for luvelta as a promising targeted therapy for NSCLC, either as monotherapy or in combination with immune checkpoint blockade. Luvelta is now being evaluated in a Phase 2 study in patients with advanced or metastatic NSCLC (NCT06555263)."
ADC • IO biomarker • Endometrial Cancer • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Lung Non-Squamous Non-Small Cell Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • CALR • EGFR • FOLR1 • HMGB1
|
|
Robert Yuan; Andrew McGeehan; Sihong Zhou; Mark Armanini; Jennifer Smith; Millicent Embry; Rhoneil Pena; Danielle K. Lewis; Krishna Bajjuri; Cuong Tran; Gang Yin; Xiaofan Li; Hanspeter Gerber; Alice Yam; Helena Kiefel; Genevive Hernandez
|